HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Profile: Symbiotec Pharmalab
Aug-21-2026

Symbiotec Pharmalab, incorporated on September 20, 2002, is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms - organic chemistry, biotechnology and complex injectables. It has leveraged its deep capabilities across organic chemistry, biotechnology, and complex injectables to operate as a contract development and manufacturing organisation (CDMO) variably for specialty pharmaceutical and nutraceutical companies globally, offering products and services across the three platforms in which it also manufactures its own products. 

Its organic chemistry capabilities include flow chemistry, hydrogenation, and photochemistry, while biotechnology capabilities include biosynthesis and biotransformation, and recombinant biologics, including Glucagon-like Peptide-1 (GLP-1) and Insulins. Further, its complex injectables capabilities include double-chamber vials, double-chamber bags and double-chamber syringes. It has a robust product portfolio of corticosteroid and steroidal-hormone APIs that are supplied globally, including Hydrocortisones, Betamethasones, Methylprednisolones, Progesterones, Estrogens and Testosterones, which are used extensively in critical care setups, as well as across chronic therapeutic areas such as respiratory, dermatology, pain management, oncology and gynaecology. 

Its broad capabilities are enabled by conversion of commodity plant-based derivative inputs (farm/ microbe-to-pharmacy approach) and work with diverse microbial strains such as bacteria, fungi, yeast and algae to convert into high value steroid and hormonal pre-cursors. This supports backward integration and underpins its ‘farm/microbe-to-pharmacy’ approach. This integration allows the company to make strategic, cost-effective ‘make versus buy’ decisions, thereby reducing external dependence for sourcing intermediates from other geographies.

Business area of the company 

The company is engaged in the business of manufacturing and selling of Active Pharmaceuticals Ingredients (API) and Intermediates. It caters to both domestic and international markets.

Products and services of the company

APIs 

  • Corticosteroid APIs
  • Steroidal-Hormone APIs
  • Classical Fermentation and Differentiated APIs

Complex Injectables

CDMO services

Awards, accreditations and recognition 

  • 2017: Received a letter of honour by the Collector - Dhar, Madhya Pradesh for the purpose of discharging corporate social responsibility by making selected government schools / hostels of the district, resource rich by developing infrastructure, creating environment and fulfilling academic requirements.
  • 2020: Received a letter of honour by the Collector - Dhar, Madhya Pradesh for discharging the company’s corporate social responsibility by actively contributing to the availability of antidotes, sanitizers, PPE kits, distribution of food packets to migrant labours, availability of transport for effective support of civil security and administration during COVID-19 at the district hospital of Dhar and the primary community and health centres in Dhar.
  • 2021: Awarded a certificate of registration for ‘ISO 14001:2015’ for the Pithampur Facility.
  • 2021: Awarded a certificate of registration for ‘ISO 14001:2018’ for the Pithampur Facility.
  • 2023: Awarded a certificate of appreciation by the U.S. Pharmacopeial Convention.
  • 2024: Received a bronze top 35% eco vadis sustainability rating by Eco Vadis.
  • 2024: Awarded a certificate of registration for ‘ISO 45001:2018 for the Pithampur Facility and Rau Facility.
  • 2024: Awarded a certificate of registration for ‘ISO 14001:2015 for the Rau Facility.
  • 2025: Awarded an international safety award merit by the British Safety Council International Safety Awards 2025.
  • 2025: Awarded a pass certificate by the British Safety Council International Safety Awards 2025.

History and milestones

  • 2004: Commenced production of APIs at the Rau Facility.
  • 2007: Investment by late Rakesh Jhunjhunwala in the company.
  • 2009: Received a letter stating that the Rau Facility meets an acceptable state of compliance with cGMP by U.S. FDA.
  • 2010: Commenced production of APIs including hormone synthesis at the Pithampur Facility.
  • 2010: Commissioned a 5 KL biotech plant at the Pithampur Facility.
  • 2010: Investment by Franklin Templeton Asset Management (India) Private Limited in the company.
  • 2012: Received a letter stating that the Pithampur Facility meets an acceptable state of compliance with the cGMP from the U.S. FDA.
  • 2013: Investment by Actis Medal Sports Limited in the company.
  • 2013: Commissioned a 35 KL fermentation project at the Pithampur Facility.
  • 2018: Investment by India Business Excellence Fund- III and Rosewood Investments in the company.
  • 2021: Expansion of a sterile plant at the Rau Facility.
  • 2023: Launched classical fermentation-based APIs at the Pithampur Facility.
  • 2025: Commissioned a complex injectables facility at the Mhow Facility.
  • 2025: Commissioned a 400 KL biomanufacturing facility at the Ujjain Facility.

  RELATED NEWS >>